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Introduction: This phase 2 study was conducted to determine the
efficacy and safety of erlotinib alone and with bortezomib in patients
with non-small cell lung cancer (NSCLC).
Methods: Patients with histologically or cytologically confirmed
relapsed or refractory stage IIIb/IV NSCLC were randomized (1:1;
stratified by baseline histology, smoking history, sex) to receive
erlotinib 150 mg/d alone (arm A; n  25) or in combination with
bortezomib 1.6 mg/m2, days 1 and 8 (arm B; n  25) in 21-day
cycles. Responses were assessed using Response Evaluation Criteria
in Solid Tumors. Tumor samples were evaluated for mutations predict-
ing response. Six additional patients received the combination in a prior
dose deescalation stage and were included in safety analyses.
Results: Response rates were 16% in arm A and 9% in arm B;
disease control rates were 52 and 45%, respectively. The study was
halted at the planned interim analysis due to insufficient clinical
activity in arm B. Median progression-free survival and overall
survival were 2.7 and 7.3 months in arm A, and 1.3 and 8.5 months
in arm B. Six-month survival rates were 56.0% in both arms;
12-month rates were 40 and 30% in arms A and B, respectively.
Response rate to erlotinibbortezomib was significantly higher in
patients with epidermal growth factor receptor mutations (50 versus
9% for wild type). The most common treatment-related grade 3
adverse event was skin rash (three patients in each treatment group).
Conclusion: Insufficient activity was seen with erlotinib plus bort-
ezomib in patients with relapsed/refractory advanced NSCLC to
warrant a phase 3 study of the combination.
Key Words: Advanced non-small cell lung cancer, Bortezomib,
Erlotinib, Phase 2.
(J Thorac Oncol. 2009;4: 1002–1009)
Lung cancer is the leading cause of cancer-related mortalityin the United States. In 2007, there were an estimated
213,380 new cases, with the disease accounting for nearly
one third of all cancer deaths.1,2 Non-small cell lung cancer
(NSCLC) represents approximately 85% of lung cancers.1
Most patients with NSCLC present with locally advanced or
metastatic disease, for which potentially curative therapy is
not available.1–3 Treatment options include chemotherapy
with or without radiation and supportive care. Standard first-
line chemotherapy for fit patients with advanced NSCLC
comprises platinum-based doublet therapy, typically resulting
in median overall survival (OS) of 8 to 11 months.4 Addition
of bevacizumab, a targeted monoclonal antibody against
vascular endothelial growth factor (VEGF), to paclitaxel-
carboplatin improves both response and survival in a select
subgroup of patients with NSCLC.5
The benefits of second-line therapy in NSCLC have
been defined within the past decade.6 The chemotherapeutic
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agents docetaxel7,8 and pemetrexed,9 along with erlotinib10
and gefitinib,11 oral agents that inhibit the epidermal growth
factor receptor (EGFR) tyrosine kinase (TK; EGFR TKIs),
are approved as single agents in this setting.6,12,13 Erlotinib
gave a 9% response rate in patients with NSCLC who had
received at least one prior therapy and demonstrated a sig-
nificant progression-free survival (PFS) advantage (2.2 ver-
sus 1.8 months, p  0.001) and OS advantage (6.7 versus 4.7
months, p  0.001) versus placebo10; promising results with
erlotinib have also been reported in highly selected groups of
previously untreated patients.14–18 However, there was no sig-
nificant survival advantage in a large placebo-controlled study of
gefitinib in patients with previously treated NSCLC.11 Gefitinib
was subsequently withdrawn in the United States and Europe
but is still used elsewhere, particularly in Asia because of a
demonstrated survival advantage in patients of Asian origin.11
Recently, third-line therapy has also been shown to be of benefit
in NSCLC.10 Erlotinib is currently the only agent approved in
this setting in North America and Europe, although gefitinib is
used elsewhere, notably Asia.
Given the limited management options for previously
treated NSCLC and the need to improve outcomes, investi-
gation of novel treatment combinations is warranted. Bort-
ezomib is a proteasome inhibitor that affects multiple signal-
ing pathways relevant to NSCLC.19–22 Preclinical studies have
shown bortezomib to have activity in NSCLC cell lines, both
alone20,23–27 and in combination with other agents.19,25,28–30
Bortezomib has demonstrated modest activity in clinical
studies in advanced NSCLC as a single agent31–33; addition-
ally, combination studies with docetaxel,32,34 gemcitabine,35
gemcitabine and carboplatin,36,37 and gemcitabine and cispla-
tin38 have shown that it can be combined with acceptable
toxicity. Anecdotal evidence suggests bortezomib may be
active in bronchioloalveolar carcinoma,39 a subset of NSCLC
in which erlotinib also is active.40
Erlotinib and bortezomib may have complementary
effects, with erlotinib blocking EGFR TK activity13 and
bortezomib causing increased degradation of activated EGFR
by 26S proteasome inhibition21,22 (and consequent reduction
in antiapoptotic and proliferative signals generated by acti-
vated EGFR). Preclinical studies of erlotinib plus bortezomib
showed that the combination had synergistic antitumor activ-
ity against the H460 NSCLC cell line (unpublished data, Mil-
lennium Pharmaceuticals, Inc., Cambridge, MA). The combina-
tion also showed more activity in H358 bronchoalveolar cells
than either agent alone; however, in other NSCLC cell lines
tested in the same study, the combination was neither additive
nor synergistic.41 Based on the results of these preclinical and
early clinical studies, the aims of this trial were to determine
the efficacy and safety of erlotinib alone or erlotinib plus
bortezomib in patients with relapsed or refractory, locally
advanced or metastatic NSCLC.
METHODS
Patients
Patients aged 18 years with histologically or cytolog-
ically confirmed, relapsed or refractory locally advanced
(stage IIIb), or metastatic (stage IV) NSCLC were eligible for
the study. Patients were required to have measurable disease
by RECIST,42 life expectancy 3 months, and Eastern Co-
operative Oncology Group performance status 1. Patients
must have received one prior line of conventional cytotoxic
chemotherapy for stage IIIb or stage IV NSCLC (excluding
adjuvant or neoadjuvant chemotherapy) and required docu-
mented progressive disease (PD) during or since their last
prior therapy. All patients provided written informed consent.
Patients were ineligible if they had received previous
treatment with bortezomib, an anti-EGFR antibody or anti-
EGFR-TKI (such as erlotinib, gefitinib, or cetuximab), or if
they had undergone chemotherapy, radiation therapy, mono-
clonal antibody therapy, or major surgery within 4 weeks
before enrollment. Those with preexisting interstitial lung
disease, grade2 peripheral neuropathy (by National Cancer
Institute Common Terminology Criteria for Adverse Events
[NCI CTCAE] version 3.0), grade 1 diarrhea or vomiting
(irrespective of antidiarrheal and/or antiemetic therapy), or
inadequate organ function were excluded.
Study Design
This two-part, randomized, noncomparative, multi-
center, open-label, phase 2 study of erlotinib (Tarceva, OSI
Pharmaceuticals, Melville, NY) alone and erlotinib plus bort-
ezomib (ELCADE, Millennium Pharmaceuticals, Inc., Cam-
bridge, MA; and Johnson & Johnson Pharmaceutical Re-
search and Development LLC, Raritan, NJ) was conducted at
19 sites in the United States and Canada from August 2005 to
July 2007. Patients received treatment in 21-day cycles; in
both parts of the study, erlotinib was administered at 150
mg/d orally, the approved dose in NSCLC, and bortezomib
was administered intravenously on days 1 and 8, at least 60
minutes after erlotinib. Study treatment continued until PD or
until another termination criterion was met, including unac-
ceptable toxicity, consent withdrawal, loss to follow-up, death,
major protocol violation, or noncompliance. The protocol was
approved by an independent ethics committee/institutional re-
view board at participating centers, in accordance with the
Declaration of Helsinki.
The objective of part 1 of the study was to determine
the maximum tolerated dose (MTD) of bortezomib in com-
bination with erlotinib, defined as the dose level at which no
more than one of at least six patients experienced predefined
dose-limiting toxicity (DLT) after completion of the first
cycle of therapy. A dose deescalation scheme was used, with
planned bortezomib doses of 1.6, 1.3, and 1.0 mg/m2 (based
on the MTD of 1.6 mg/m2 in a phase 1 trial in patients with
advanced solid tumors).43 Six patients were enrolled at the
initial dose of 1.6 mg/m2. No DLTs were reported; this dose
was identified as the MTD and used for part 2.
In part 2, patients were randomized (1:1) to receive
erlotinib alone (arm A) or erlotinib plus bortezomib 1.6
mg/m2 (arm B). Neither patients nor physicians were blinded
regarding treatment assignment. Randomization was strati-
fied by baseline histology (adenocarcinoma versus other),
smoking history (smoking versus nonsmoking), and gender
(male versus female), to balance for factors associated with a
greater likelihood of response to erlotinib (female gender,
never smokers, adenocarcinoma histology).10–13 Erlotinib
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and/or bortezomib doses were withheld or reduced as neces-
sary according to predefined criteria. If required, the erlotinib
dose was reduced in 50-mg intervals; up to three dose
reductions were allowed for bortezomib (1.63 1.33 1.03
0.7 mg/m2). Supportive care medications permitted included
antiemetics, loperamide for diarrhea, colony-stimulating fac-
tors, antiinflammatory drugs, bisphosphonates, and topical or
oral treatments for rash. Treatment with cytotoxic chemother-
apeutic agents, and other monoclonal antibodies or investi-
gational agents was prohibited.
Efficacy, Safety, and Other Measurements
The primary end point was tumor response rate (com-
plete response  partial response using RECIST42) in the
intent to treat (ITT) population. In part 2, disease assessment
was performed by investigators every 6 weeks until PD.
Secondary end points included disease control rate (complete
response  partial response  stable disease), time to pro-
gression (TTP), PFS, OS, 6-month and 12-month survival
rates, and safety and tolerability. Adverse events (AEs) were
assessed throughout treatment and for 30 days after last dose
of study treatment and were graded using NCI CTCAE 3.0.
An additional objective was the evaluation of banked
tumor tissue for EGFR and v-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog (KRAS) mutation status and corre-
lation with response. DNA was prepared from 100-m sec-
tions of whole blocks or tissue scraped off and pooled from
TABLE 1. Patient Demographics and Baseline Characteristics
Erlotinib Alone
Arm A (ITT),
(n  25)
Erlotinib Plus Bortezomib
Characteristic
Arm B (ITT),
(n  25)
Safety,
(n  31)
Age, yr
Median 64 62 62
Range 45–82 36–81 36–81
Sex, n (%)
Female 12 (48) 14 (56) 15 (48)
Male 13 (52) 11 (44) 16 (52)
Race, n (%)
White 20 (80) 21 (84) 26 (84)
Black 3 (12) 1 (4) 2 (6)
Asian/Pacific Islander 2 (8) 1 (4) 1 (3)
Other 0 2 (8) 2 (6)
ECOG performance status, n (%)
0 7 (28) 7 (29) 8 (27)
1 18 (72) 16 (67) 21 (70)
3 0 1 (4) 1 (3)
Unknown 0 1 1
Time from initial diagnosis to randomization, mo n  23 n  24 n  24
Median 10.3 8.9 8.9
Range 5–37 2–34 2–34
Histologic classification, n (%)
Adenocarcinoma 14 (56) 14 (56) 16 (52)
Squamous cell carcinoma 7 (28) 7 (28) 10 (32)
Pure bronchioloalveolar carcinoma 0 1 (4) 1 (3)
Large cell carcinoma 1 (4) 0 0
Other 3 (12) 3 (12) 4 (13)
TNM stage, n (%)
Stage IIIb 3 (12) 4 (16) 7 (23)
Stage IV 22 (88) 21 (84) 24 (77)
History of smoking (ever smoked), n (%)
Yes 20 (80) 21 (84) 27 (87)
No 5 (20) 4 (16) 4 (13)
No. of prior lines of therapy, n (%)
0 3 (12) 1 (4) 1 (3)
1 21 (84) 19 (76) 24 (77)
2 or more 1 (4) 5 (20) 6 (19)
Prior platinum-based therapy, n (%) 19 (76) 22 (88) 28 (90)
Prior single-agent therapy, n (%) 2 (8) 2 (8) 2 (6)
ECOG, Eastern Cooperative Oncology Group; ITT, intent to treat.
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2 to 3 glass slides. Profiling for KRAS mutations was per-
formed using polymerase chain reaction (PCR)/ligase detec-
tion reaction.44 EGFR mutation detection was performed
using PCR/ligase detection reaction44 and capillary electro-
phoresis,45 plus fluorescent PCR using primers flanking the
hotspot for insertions/deletions in exon 19.
Statistical Methods
This was a noncomparative study; there was no formal
statistical comparison between treatment arms. Based on
Simon’s two-stage optimal design, a sample size of 80 pa-
tients (40 per arm) was determined. This would provide 80%
power to reject the null hypothesis response rate of 9% at a
significance level of   0.15 when the true response rate
was 20%. To ensure that at least 80 patients (40 per arm)
enrolled in part 2 were evaluable for response in the final
analysis, it was planned to enroll approximately 100 patients
overall (part 1 and part 2). An interim analysis of objective
tumor response for arm B was planned, to provide the option
to discontinue the study early should the combination not
demonstrate sufficient effectiveness (fewer than two objec-
tive responses in the first 19 response-evaluable patients who
had the opportunity to complete a minimum of four cycles of
therapy).
The ITT population included all randomized patients
(part 2) who received at least one dose of treatment. This
population was intended to be used for all efficacy analyses.
Response and disease control rates were calculated with
two-sided 95% confidence intervals. TTP, PFS, and OS were
analyzed using Kaplan-Meier estimates. The safety popula-
tion included all patients enrolled in part 1 and part 2 who
received at least one dose of treatment. Safety data including
treatment-emergent AEs (those that occurred or worsened from
baseline during treatment or within 30 days after the last dose),
treatment-related AEs, and serious AEs were tabulated.
RESULTS
Patient Demographics and Disposition
Between August 2005 and June 2006, the study en-
rolled 57 patients; six were treated at the bortezomib 1.6
mg/m2 dose level in part 1, and 51 were randomized to
erlotinib (arm A; n  25) or erlotinib plus bortezomib (arm
B; n  26) in part 2. One patient randomized to arm B
provided informed consent but was withdrawn 4 days after
randomization because of PD and did not receive study
treatment; therefore, 50 patients were included in the ITT
population and 56 in the safety population (see Supplemen-
tary Figure 1, Supplemental Digital Content 1, Available at:
http://links.lww.com/A1283). Baseline demographics and
clinical characteristics were comparable between treatment
groups and between arms in part 2 (Table 1). In arm A,
patients received erlotinib for a mean of 17.5 weeks; mean
total dose was 17.1 g, with mean relative dose intensity of
92%. In the combination treatment group (arm B plus part 1
patients), patients received erlotinib for a mean of 11.1
weeks; mean total dose was only 10.4 g, although mean
relative dose intensity was 97%. Patients received bortezomib
for a mean of 9.4 weeks; mean total dose was 10.9 mg/m2,
and mean relative dose intensity was 93%. Erlotinib and
bortezomib exposure was similar between patients in part 1
FIGURE 1. Best percent change in tumor size in target lesions in patients in arm A (erlotinib alone) and arm B (erlotinib
plus bortezomib). In arm A, the patient represented by the second line from the left achieved complete response by RECIST,
and the patients represented by the first, fourth, and fifth lines from the left achieved partial response by RECIST. In arm B,
the patients represented by the first and third lines from the left achieved partial response by RECIST.
TABLE 2. Best Response to Treatment (ITT Population)
Response
Arm A
Erlotinib Alone
(n  25)
Arm B Erlotinib
Plus Bortezomib
(n  22)a
Overall response (CR  PR),
n (%)
4 (16) 2 (9)
95% CI (%) 4.5–36.1 1.1–29.2
Disease control (CR  PR  SD),
n (%)
13 (52) 10 (45)
95% CI (%) 31.3–72.2 24.4–67.8
Complete response (CR), n (%) 1 (4) 0
Partial response (PR), n (%) 3 (12) 2 (9)
Stable disease (SD), n (%) 9 (36) 8 (36)
Progressive disease (PD), n (%) 11 (44) 11 (50)
Inevaluable, n (%) 1 (4) 1 (5)
a Response data missing for three patients in arm B. Only one of the first 19
response-evaluable patients achieved a response.
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and part 2. Patients completed a median of two treatment
cycles of bortezomib in part 2 (range 1–18).
Response and Survival
The response rate was 16% in arm A and 9% in arm B;
disease control rates were 52 and 45%, respectively (Table 2).
Individual patient responses in terms of best percentage
tumor reduction in target lesions are shown in Figure 1. Per
protocol, enrollment was halted as of September 22, 2006
because of insufficient clinical activity in arm B.
Kaplan-Meier distribution curves of TTP, PFS, and OS
are presented in Figure 2. Median TTP was 2.7 months in arm
A and 1.5 months in arm B; median PFS was 2.7 months and
1.3 months, respectively. Intensity of skin rash correlated
with PFS, although this correlation was not significant (p 
0.17); median PFS was 2.8 months versus 1.3 months for
patients with grade 2/3 versus grade 0/1 skin rash. After
median follow-up of 14 months, median OS was 7.3 months
in arm A and 8.5 months in arm B. The 6-month survival rate
was 56% in both treatment arms; 12-month survival rates
were 40 and 30% in arm A and arm B, respectively.
Biomarker Analyses
Sufficient tumor tissue samples for biomarker analysis
were obtained from 32 patients; 31 were evaluable for KRAS
mutations and 29 for EGFR mutations. KRAS mutations were
observed in 11/31 (35%) evaluable samples and EGFR mu-
tations in 6/29 (21%) evaluable samples. Frequencies of
KRAS and EGFRmutations in arm A were 35 (6/17) and 27%
(4/15), respectively, and in arm B, 36 (5/14) and 14% (2/14),
respectively. Responses according to KRAS and EGFR mu-
tation status are shown in Table 3. There was no significant
correlation between TTP or PFS and KRAS mutation status,
either overall or within treatment arms (data not shown).
Median TTP (13.6 months versus 2.0 months) and PFS (4.3
months versus 1.5 months) were longer in patients with
tumors with an EGFR mutation versus those with EGFR
wild-type tumors, although differences were not signifi-
cant. Similar trends were observed within treatment arms
(data not shown).
Safety
The majority of patients in each treatment group expe-
rienced at least one AE (Table 4). The most commonly
reported AEs were acneiform rash (88% of patients receiving
erlotinib, 74% of patients receiving erlotinib plus bort-
ezomib), diarrhea (72%, 48%), and fatigue (60%, 42%).
Incidences of grade 3 AEs and treatment-related grade 3
AEs are summarized in Table 4. The most common treat-
ment-related grade 3 AE was skin rash (rash or dermatitis
acneiform), reported by three patients receiving erlotinib
alone (12%) and three patients receiving erlotinib plus bort-
ezomib (10%). Only one serious AE, of pneumonia, in a
patient receiving erlotinib plus bortezomib in part 2, was
considered treatment related; this was the only treatment-
related AE leading to death during the study.
DISCUSSION
Bortezomib and erlotinib both have demonstrated sin-
gle-agent activity in previously treated advanced NSCLC10,32
FIGURE 2. Kaplan-Meier plots for (a) time to progression
(TTP), (b) progression-free survival (PFS), and (c) overall sur-
vival (OS) (intent to treat [ITT] population).
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and may have complementary mechanisms of action.13,21,22
Preclinical data suggested that the combination of erlotinib
and bortezomib may have greater antitumor activity than
either agent alone (unpublished data, Millennium Pharmaceu-
ticals).41 However, despite this, the results of this randomized
phase 2 study in patients with relapsed or refractory NSCLC
did not indicate a response or survival benefit when bort-
ezomib was added to erlotinib. The response rate was 16%
with erlotinib alone, and 9% with erlotinib plus bortezomib,
which is not different from the reported 9% response rate for
single-agent erlotinib in patients with previously treated
NSCLC.10 Median TTP and PFS were both 2.7 months in arm
A, and 1.5 months and 1.3 months, respectively, in arm B;
median OS was 7.3 months for erlotinib alone and 8.5 months
for erlotinib plus bortezomib. Therefore, the study was halted
at the planned interim analysis due to insufficient clinical
activity with the combination treatment. It is not clear why
erlotinib plus bortezomib in the clinical setting failed to
reflect the additive activity demonstrated in preclinical stud-
ies; it is possible that preexposure to erlotinib may abrogate
the activity of bortezomib due to disruption of the cell cycle
at different phases.41
Both treatment regimens were fairly well tolerated
during the study; AEs were consistent with the known safety
profiles of erlotinib and bortezomib.10,32 The rates of grade 3
AEs previously reported as DLTs in phase 1 studies of
bortezomib in solid tumors,31,43 including diarrhea, hypoten-
sion, and peripheral neuropathy, were limited in arm B,
because of the lower dose and/or dose intensity of bortezomib
used in this study compared with those at which the DLTs
typically occurred, as well as the limited duration of treat-
ment. There was no notable additional toxicity with the
combination of erlotinib and bortezomib. The most common
treatment-related grade 3 AE was skin rash, reported by three
patients in each treatment group. Skin rash is a common AE
in clinical trials with EGFR-targeted agents such as erlo-
tinib.13,46 In this study, the severity of skin rash correlated
positively with PFS in the ITT population. A previous anal-
ysis of two large phase 2 studies of erlotinib in NSCLC and
pancreatic cancer also showed a strong correlation between
occurrence of rash and survival, with longer PFS and
disease control correlated with increasing rash severity.47
Thus, rash may be a surrogate marker of clinical benefit
with erlotinib, although the mechanism underlying its
development remains unclear.46
This study found no significant correlation between
presence of KRAS mutations and response rate, TTP, or PFS,
although KRAS mutation has previously been identified as a
predictor of resistance to EGFR-TKI therapy in NSCLC.48 In
contrast, a significantly higher response rate was seen in
patients with tumors with an EGFR mutation versus those
with EGFR wild-type tumors. Notably, the two patients with
KRAS mutations who responded also had EGFR mutations, a
rare finding as these mutations have been shown in most but
not all studies to be mutually exclusive. The presence of
EGFR mutations seems to be a potential indicator of in-
creased responsiveness to erlotinib.13,49,50 EGFR mutations
also seem to be associated with longer survival overall in
NSCLC, compared with wild-type EGFR, although to date,
randomized trial data have not confirmed that they predict a
TABLE 3. Response to Treatment According to KRAS and EGFR Mutation Status in all Evaluable Patients and by Treatment
Arm
Responses, n/N
(%)
KRAS Mutation Status EGFR Mutation Status
All (n  31) Arm A (n  17) Arm B (n  14) All (n  29) Arm A (n  15) Arm B (n  14)
Mutation 2/11 (18%) 2/6a (33%) 0/5 (0%) 3/6 (50%) 2/4 (50%) 1/2 (50%)
Wild type 4/20 (20%) 2/11 (18%) 2/9 (22%) 2/23 (9%) 2/11 (18%) 0/12 (0%)
p 1.0 0.58 0.51 0.046 0.52 0.014
a Both responding patients also had EGFR mutations.
EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog.
TABLE 4. Summary of Treatment-Emergent AEs and
On-Study Deaths (Safety Population)
Erlotinib Alone
(n  25)
Erlotinib Plus
Bortezomib
(n  31)
Any AE, n (%) 25 (100) 30 (97)
Any treatment-related AE,
n (%)
23 (92) 28 (90)
Any grade 3 AE, n (%) 15 (60) 18 (58)
Any treatment-related grade
3 AE, n (%)
4 (16) 7 (23)
Treatment-related grade 3 AEs
Rash or dermatitis
acneiform
3 (12) 3 (10)
Diarrhea NOS 0 1 (3)
Nausea/vomiting NOS 0 1 (3)
Paraesthesia 1 (4) 0
Peripheral neuropathy
aggravated
0 1 (3)
Hypokalemia 0 1 (3)
Any SAE 10 (40) 12 (39)
Any treatment-related SAE 0 1 (3)a
AE leading to discontinuation 6 (24) 5 (16)
AE leading to dose reduction 5 (20) 6 (19)
AE leading to dose interruption 3 (12) 11 (35)
Deaths within 30 d of last
dose of study drug
6 (24) 7 (23)
Deaths due to treatment-
related AEs
0 1 (3)a
AE, adverse event; NOS, not otherwise specified; SAE, serious adverse event.
a One patient with grade 5 pneumonia.
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differentially greater survival benefit from EGFR-TKI therapy.49–52
In this study, patients with EGFR mutations demonstrated
longer TTP and PFS than those with wild-type EGFR. Al-
though it is not yet clear whether EGFR protein expression
predicts response or differential survival benefit in response
to EGFR-TKI therapy,49,52–54 studies have demonstrated a
significant survival benefit with EGFR-TKI therapy versus
placebo in EGFR-positive patients but no significant benefit
for EGFR-negative patients.49,52 Moreover, high EGFR gene
copy number by fluorescence in situ hybridization has been
shown to be predictive of a differentially greater survival
benefit from erlotinib50 and gefitinib.52 No analyses of EGFR
protein expression or EGFR gene copy number were con-
ducted in this study.
There is a clear need for therapies that increase re-
sponse and survival rates in advanced NSCLC. Given the
multilevel cross-stimulation between pathways involved in
cancer cell survival and replication, combining targeted ther-
apies to block multiple signaling pathways may provide
additional antitumor activity.55 Several targeted combinations
for first-line therapy or subsequent-line therapy are being
explored in advanced NSCLC. Erlotinib is being investigated
in combination with the VEGF monoclonal antibody bevaci-
zumab, the multitargeted antifolate agent pemetrexed, sor-
afenib (a potent Raf-1 inhibitor that is also active against
VEGFR-2, VEGFR-3, and platelet-derived growth factor
receptor), and the mammalian target of rapamycin inhibi-
tor everolimus.13 Clinical trials in advanced NSCLC are
also exploring the use of bortezomib in combination with
other targeted agents including pemetrexed and bevaci-
zumab (with carboplatin).
In conclusion, this study did not show a benefit with the
combination of erlotinib and bortezomib in patients with
previously treated advanced NSCLC. Thus, a phase 3 study
of this combination in this patient population is not sup-
ported. Nevertheless, combining erlotinib with other active
targeted agents remains a potentially promising strategy in
this setting. This study shows the value of performing ran-
domized phase 2 trials of novel combinations in advanced
NSCLC; this approach is recommended before large phase 3
trials are initiated.
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